An Amphiphilic Mimotope Vaccine to Enhance FDA-Approved Anti-CD19 CAR T Therapy

Exclusively Licensed

Researchers

Darrell J Irvine / Benjamin Cossette / Leyuan Ma / Naveen Mehta / Karl Dane Wittrup

Departments: David H Koch Institute for Integrative Cancer Res, Department of Chemical Engineering
Technology Areas: Biotechnology: Biomanufacturing, Synthetic Biology / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living

  • chimeric antigen receptor-targeting ligands and uses thereof
    United States of America | Published application

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies